Nymox Pharmaceutical Corp (NYMX)

NASDAQ
0.3890
-0.0010(-0.26%)
After Hours
0.3700
-0.0190(-4.8843%)
- Real-time Data
  • Volume:
    37,632
  • Day's Range:
    0.3815 - 0.3900
  • 52 wk Range:
    0.1850 - 2.2700

NYMX Overview

Prev. Close
0.39
Day's Range
0.3815-0.39
Revenue
-
Open
0.39
52 wk Range
0.185-2.27
EPS
-0.18
Volume
37,632
Market Cap
35.12M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
457,176
P/E Ratio
-
Beta
1
1-Year Change
-75.53%
Shares Outstanding
90,279,794
Next Earnings Date
Aug 15, 2022
What is your sentiment on Nymox Pharmaceutical?
or
Market is currently closed. Voting is open during market hours.

Nymox Pharmaceutical Corp News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Nymox Pharmaceutical Corp Analysis

Nymox Pharmaceutical Corp Company Profile

Nymox Pharmaceutical Corp Company Profile

Employees
0

Nymox Pharmaceutical Corporation is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. Its products include Fexapotide Triflutate, NicAlert and TobacAlert. Fexapotide Triflutate is a protein injectable for benign prostatic hyperplasia (prostate enlargement, BPH) and for low-grade localized prostate cancer. NicAlert is a simple test to determine smoking status. TobacAlert is a home test that provides an on-the-spot determination of a person’s level of exposure to tobacco products, including secondhand smoke. The Company’s lead drug candidate for BPH FT has completed Phase III development in more than 70 clinical centers in the United States. FT has completed a phase II trial in the United States. It has also developed the AlzheimAlert test. The Company operates in Canada, the United States and Switzerland.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyNeutralStrong Sell
Technical IndicatorsStrong BuyBuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyBuyStrong Sell
  • It will be double
    0
    • This stock has a superior Risk/return - approaching a decision on a new drug in a huge market (enlarged prostate and prostate cancer).  HEAVY Insider buying and positive indications toward an approval in a European Decentralized Approval process.  Will send the stock up 3 fold minimum.  A disapproval will send it down 3 points.  Buy it.
      0